Skip to main navigation menu Skip to main content Skip to site footer

Vol. 12 No. 10 (2025)
International Multidisciplinary Journal for Research & Development

Articles

SCIENTIFIC BASIS FOR INDIVIDUALIZATION AND OPTIMIZATION OF THERAPY FOR AIRBORNE DISEASES IN CHILDREN: A COMPREHENSIVE REVIEW

Published 2025-10-17

  • Oripova Jamila Nematovna

Oripova Jamila Nematovna
Department of Infectious diseases, Andijan State Medical Institute, Andijan, Uzbekistan

Abstract

Airborne diseases represent one of the most significant causes of morbidity and mortality in pediatric populations worldwide, imposing a substantial burden on healthcare systems. The conventional "one-size-fits-all" therapeutic approach to managing these infections, including pneumonia, bronchitis, influenza, and respiratory syncytial virus (RSV), is increasingly being challenged by the rise of antimicrobial resistance (AMR), high rates of treatment failure, and the potential for adverse drug reactions in children. The unique physiological and immunological characteristics of children, which undergo dynamic changes from infancy to adolescence, necessitate a more nuanced and personalized treatment strategy. This review article aims to provide a comprehensive scientific rationale for the individualization and optimization of therapy for airborne diseases in children. We explore the critical interplay of host factors (genetics, age-related pharmacokinetics/pharmacodynamics (PK/PD), immune status, microbiome) and pathogen characteristics (genotype, resistance patterns) in determining clinical outcomes. The paper synthesizes current evidence on advanced diagnostics, biomarker-guided therapies, pharmacogenomics, and therapeutic drug monitoring as key pillars for developing tailored treatment regimens. The central thesis is that a shift from empirical to precision-based therapy is not merely an academic pursuit but a clinical imperative to enhance therapeutic efficacy, minimize toxicity, and combat the growing threat of AMR. We discuss the integration of multi-omics data and computational modeling as future directions for creating dynamic, adaptive treatment protocols that can significantly improve the standard of care for children suffering from airborne infections.

Keywords

Airborne Diseases, Pediatrics, Personalized Medicine, Therapy Optimization, Pharmacogenomics, Antimicrobial Resistance, Biomarkers, Pharmacokinetics, Individualized Therapy.

PDF

References

  1. World Health Organization. (2023). Pneumonia in children. WHO. https://www.who.int/news-room/fact-sheets/detail/pneumonia
  2. Laxminarayan, R., Duse, A., Wattal, C., Zaidi, A. K., Wertheim, H. F., Sumpradit, N., ... & Cars, O. (2013). Antibiotic resistance—the need for global solutions. The Lancet Infectious Diseases, 13(12), 1057-1098. https://doi.org/10.1016/S1473-3099(13)70318-9
  3. Le, J., & Cies, J. J. (2017). A review of the pharmacokinetics and pharmacodynamics of vancomycin in pediatric patients. Journal of Pediatric Pharmacology and Therapeutics, 22(4), 244-257. https://doi.org/10.5863/1551-6776-22.4.244
  4. Relling, M. V., & Evans, W. E. (2015). Pharmacogenomics: translating functional genomics into rational therapeutics. Science, 349(6245), aab2222. https://doi.org/10.1126/science.aab2222
  5. Schuetz, P., Christ-Crain, M., & Müller, B. (2012). Procalcitonin and other biomarkers to improve assessment and antibiotic stewardship in infections—a personal view. Swiss Medical Weekly, 142, w13562. https://doi.org/10.4414/smw.2012.13562
  6. Tsoni, K., & Tsolia, M. (2021). The role of molecular diagnostics in pediatric respiratory tract infections. Current Opinion in Pediatrics, 33(2), 226-233. https://doi.org/10.1097/MOP.0000000000000994
  7. van der Zalm, M. M., Uiterwaal, C. S., Wilbrink, B., de Jong, B. M., Verheij, T. J., & van der Ent, C. K. (2011). A prospective study on the severity of respiratory syncytial virus infections in children in primary care. Pediatric Pulmonology, 46(7), 685-692. https://doi.org/10.1002/ppul.21415
  8. Germovsek, E., Barker, C. I., Sharland, M., & Hsia, Y. (2017). Pharmacokinetic-pharmacodynamic modeling in pediatric drug development, and the importance of standardized scaling of clearance. Journal of Clinical Pharmacology, 57, S68-S78. https://doi.org/10.1002/jcph.844
  9. Beaudoin, J. J., & Tsalik, E. L. (2019). Host-response-based diagnostics for infectious diseases: a new paradigm for the clinical microbiology laboratory. Clinical Microbiology Reviews, 32(3), e00057-18. https://doi.org/10.1128/CMR.00057-18
  10. Kearns, G. L., Abdel-Rahman, S. M., Alander, S. W., Blowey, D. L., Leeder, J. S., & Kauffman, R. E. (2003). Developmental pharmacology—drug disposition, action, and therapy in infants and children. New England Journal of Medicine, 349(12), 1157-1167. https://doi.org/10.1056/NEJMra035092
  11. Principi, N., & Esposito, S. (2016). Biomarkers in pediatric community-acquired pneumonia. International Journal of Molecular Sciences, 17(9), 1534. https://doi.org/10.3390/ijms17091534
  12. Ur-Rehman, T., Jones, G. D., & Carcillo, J. A. (2020). The role of precision medicine in pediatric sepsis. Expert Review of Precision Medicine and Drug Development, 5(2), 99-114. https://doi.org/10.1080/23808993.2020.1730701

Downloads

Download data is not yet available.